These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6410202)

  • 21. [Reduction of hyperfibrinemia in the nephrotic syndrome using defibrase].
    Salvadori JM; Follana R; Olmer M
    J Urol Nephrol (Paris); 1975 Sep; 81(9):691-6. PubMed ID: 1214313
    [No Abstract]   [Full Text] [Related]  

  • 22. [Modified dosage scheme for the subcutaneous use of arvin in patients with chronic arterial occlusive diseases].
    Ehrly AM; Köhler HJ
    Vasa; 1976; 5(2):155-62. PubMed ID: 973426
    [No Abstract]   [Full Text] [Related]  

  • 23. Controlled evaluation of drugs in chronic vascular disease.
    Trübestein G
    Angiology; 1981 Oct; 32(10):699-704. PubMed ID: 6173001
    [No Abstract]   [Full Text] [Related]  

  • 24. Subcutaneous ancrod therapy in peripheral arterial disease: improvement in blood viscosity and nutritional blood flow.
    Lowe GD; Morrice JJ; Forbes CD; Prentice CR; Fulton AJ; Barbenel JC
    Angiology; 1979 Sep; 30(9):594-9. PubMed ID: 484913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic effects on metabolism by lowering of blood viscosity (defibrase)].
    Köhler M; Martin M; Krüpe M
    Verh Dtsch Ges Inn Med; 1973; 79():1400-2. PubMed ID: 4799542
    [No Abstract]   [Full Text] [Related]  

  • 26. [Defibrination with ancrod (arvin) in peripheral arterial occlusive diseases. Principle, indications, contraindications technic and course].
    Heidrich H
    ZFA (Stuttgart); 1978 Nov; 54(32):1648-51. PubMed ID: 735320
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapeutic defibrination with ancrod (author's transl)].
    Ehringer H; Dudczak R; Lechner K
    Dtsch Med Wochenschr; 1973 Nov; 98(48):2298-304. PubMed ID: 4797013
    [No Abstract]   [Full Text] [Related]  

  • 28. [New possibilities in the rheologic-therapeutic influencing of blood viscosity in angiologic diseases].
    Ehrly AM; Glatz A; Scheinpflug W
    Verh Dtsch Ges Inn Med; 1974; 80():1450-2. PubMed ID: 4454453
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term results after defibrinogenation by Arwin in chronic occlusive arterial disease.
    Staiger J; Konrad-Graf S; Keil G
    Bibl Haematol; 1981; (47):252-7. PubMed ID: 7337665
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapy of chronic peripheral arterial occlusive diseases with snake venom enzyme Arwin].
    Ehrly AM
    Med Welt; 1975 Mar; 26(10):446-55. PubMed ID: 1123988
    [No Abstract]   [Full Text] [Related]  

  • 31. [Arvin--a new therapeutic agent].
    Ehrly AM
    Med Welt; 1978 Jul; 29(27-28):1144-5. PubMed ID: 672584
    [No Abstract]   [Full Text] [Related]  

  • 32. [Incidence of peptic ulcer in an inpatient angiologic patient sample].
    Creutzig A; Horstkotte H; Fischer M; Kleine P; Brunner G; Alexander K
    Leber Magen Darm; 1984 Jul; 14(4):161-3. PubMed ID: 6482641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Arterial occlusive disease: reducing blood viscosity through drugs].
    Gnauen H
    Med Klin; 1981 Feb; 76(5):144-6. PubMed ID: 7219342
    [No Abstract]   [Full Text] [Related]  

  • 34. Arwin in peripheral arterial circulatory disorders: controlled multicentre trials.
    Wolf GK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):387-92. PubMed ID: 786664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice.
    Chmielewska J; Poggi A; Janik P; Latallo ZS; Donati MB
    Eur J Cancer (1965); 1980 Jul; 16(7):919-23. PubMed ID: 7000518
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antimetastatic effect of batroxobin].
    Shibuya M; Aoyama A; Kawachi S; Baba M; Murata A; Sakai S; Ohtsuka M; Matsusaka M; Niitani H
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):732-4. PubMed ID: 3548597
    [No Abstract]   [Full Text] [Related]  

  • 37. [Defibrination in the therapy of arterial occlusive diseases].
    Böhme H
    ZFA (Stuttgart); 1978 Nov; 54(32):1644-7. PubMed ID: 735319
    [No Abstract]   [Full Text] [Related]  

  • 38. Defibrinogenation treatment in patients suffering from severe intermittent claudication - a controlled study.
    Martin M; Hirdes E; Auel H
    Thromb Res; 1976 Jul; 9(1):47-57. PubMed ID: 785691
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hemocoagulant effect of Topical Reptilase].
    Sigurta D
    Dent Cadmos; 1986 Oct; 54(15):87-9. PubMed ID: 3552764
    [No Abstract]   [Full Text] [Related]  

  • 40. [Therapeutic effect of blood viscosity in stroke].
    Heiss WD
    Beitr Infusionther Klin Ernahr; 1981; 8():22-32. PubMed ID: 6172108
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.